내인성 에스트로겐과 혈관 질환 위험인자와의 연관성
Relationships between Endogenous Estrogen and the Risk Factors for Vascular Disease
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Background: This study evaluated the relationships between endogenous estrogen levels and vascular risk factors in healthy men and women. Methods: Demographics and laboratory data were collected from normotensive subjects (123 men and 154 women) in their thirties, forties and fifties who had normal laboratory profiles and no cardiovascular risk factors. Initially, estradiol, low-density lipoprotein (LDL)-cholesterol, triglyceride, and high-density lipoprotein (HDL)-cholesterol, systolic and diastolic blood pressure (SBP and DBP), NO2/NO3, homocysteine, and body mass index (BMI) were measured. Then, the relationships between estradiol and the evaluated items were analyzed with comparison of means and correlation, and stepwise multiple regression analysis based on genders and age-groups. Results: Estradiol levels decreased with aging in women. Lower LDL and triglyceride, higher HDL levels, and lower SBP and DBP observed in women were correlated with decreasing age as well as increasing estradiol level. On the multivariate analysis, however, estradiol levels were negatively correlated with the changes in SBP, DBP, and triglyceride among the lipid variables. BMI was positively related with the increase of SBP and DBP and the estradiol levels. Al-though higher NO2/NO3 and lower homocysteine levels were observed in women than men, the NO2/NO3 and homocysteine levels had no significant correlation with estradiol changes. Conclusion: The study observed the beneficial relationships between endogenous estrogen, and blood pressures and lipids in healthy women. The estrogen-related benefits observed in this study were lower TG levels, SBP, and DBP in young women than those in older women or in men. (Korean J Stroke 2011;13:20-26)
Abstract
Background: This study evaluated the relationships between endogenous estrogen levels and vascular risk factors in healthy men and women. Methods: Demographics and laboratory data were collected from normotensive subjects (123 men and 154 women) in their thirties, forties and fifties who had normal laboratory profiles and no cardiovascular risk factors. Initially, estradiol, low-density lipoprotein (LDL)-cholesterol, triglyceride, and high-density lipoprotein (HDL)-cholesterol, systolic and diastolic blood pressure (SBP and DBP), NO2/NO3, homocysteine, and body mass index (BMI) were measured. Then, the relationships between estradiol and the evaluated items were analyzed with comparison of means and correlation, and stepwise multiple regression analysis based on genders and age-groups. Results: Estradiol levels decreased with aging in women. Lower LDL and triglyceride, higher HDL levels, and lower SBP and DBP observed in women were correlated with decreasing age as well as increasing estradiol level. On the multivariate analysis, however, estradiol levels were negatively correlated with the changes in SBP, DBP, and triglyceride among the lipid variables. BMI was positively related with the increase of SBP and DBP and the estradiol levels. Al-though higher NO2/NO3 and lower homocysteine levels were observed in women than men, the NO2/NO3 and homocysteine levels had no significant correlation with estradiol changes. Conclusion: The study observed the beneficial relationships between endogenous estrogen, and blood pressures and lipids in healthy women. The estrogen-related benefits observed in this study were lower TG levels, SBP, and DBP in young women than those in older women or in men. (Korean J Stroke 2011;13:20-26)
참고문헌 (24)
- Barrett-Connor E, "Sex differences in coronary heart disease. 1. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture", Circulation, 95, pp.252~264 (1997)
- Huang A, "Gender-specific regulation of cardiovascular function: estrogen as key player", Microcirculation, 11, pp.9~38 (2004)
- Kuller LH, "Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women’s Health Initiative", Arterioscler Thromb Vasc Biol, 23, pp.11~16 (2003)
- Smolders RG, "Estrogens, homocysteine, vasodilatation and menopause: basic mechanisms, interactions and clinical implications", Gynecol Endocrinol, 17, pp.339~354 (2003)
- Grodstein F, "Postmenopausal hormone use and secondary prevention of coronary events in the nurses’ health study. a prospective, observational study", Ann Intern Med, 135, pp.1~8 (2001)
- Machens K, "Issues to debate on the Women’s Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma", Hum Reprod, 18, pp.1992~1999 (2003)
- Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
- Grady D, "Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen", progestin Replacement Study follow-up (HERS II), 2002, pp.288, 49~57
- Moshage H, "Nitrite and nitrate determinations in plasma: a critical evaluation", Clin Chem, 41, pp.892~896 (1995)
- Verdon CP, "Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite", Anal Biochem, 224, pp.502~508 (1995)
- Giovannoni G, "Adaptation of the nitrate reductase and Griess reaction methods for the measurement of serum nitrate plus nitrite levels", Ann Clin Biochem, 34, pp.193~198 (1997)
- Kratz A, "Appendices: Laboratory values of clinical importance, in Harrison’s Principles of Internal Medicine. 16 ed", pp.A-62~A-7 (2005), McGraw-Hill
- Mackey RH, "Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study", Arch Intern Med, 165, pp.510~515 (2005)
- "Effects of estrogen or estrogen", progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen, JAMA, pp.1995, 273[DOI]
- Pripp U, "A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease", J Hypertens, 17, pp.1379~1386 (1999)
- Mueck AO, "Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women", Maturitas, 49, pp.189~203 (2004)
- Seely EW, "Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women", Hypertension, 33, pp.1190~1194 (1999)
- Wassertheil-Smoller S, "Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative", Hypertension, 36, pp.780~789 (2000)
- Reckelhoff JF, "Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging", Life Sci, 55, pp.1895~1902 (1994)
- Wellman GC, "A proposed mechanism for the cardioprotective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity", Clin Exp Pharmacol Physiol, 23, pp.260~266 (1996)
- Weiner CP, "Induction of calcium-dependent nitric oxide synthases by sex hormones", Proc Natl Acad Sci USA, 91, pp.5212~5216 (1994)
- Dimitrova KR, "Estrogen and homocysteine", Cardiovasc Res, 53, pp.577~588 (2002)
- Nurk E, "Changes in lifestyle and plasma total homocysteine: the Hordaland Homocysteine Study", Am J Clin Nutr, 79, pp.812~819 (2004)
- Fakhrzadeh H, "Total plasma homocysteine, folate, and vitamin B12 status in healthy Iranian adults: the Tehran homocysteine survey (2003-2004)", a cross-sectional population based study, 2006, pp.6, 29~